Resihance 40mg (Regorafenib) is a resourceful drug utilized for patients with metastatic colorectal (parts of the large intestine) cancer (CRC) who were given other cancer drugs (chemotherapy) beforehand. If CRC is left untreated, it could spread throughout the body.
Regorafenib has multi-action potential wherein it stops various proteins involved in,
- Growth and multiplication of cancer cells (Cell-proliferation)
- Normal functioning of cancer cells (Cell-stability)
- Progression of cancer cells (Oncogenesis)
- Blood flow to cancer cells (Angiogenesis)
Additionally, Resihance 40 mg (Regorafenib) is also specified for patients with liver cancer and gastrointestinal stromal tumors (Cancer of stomach and intestine) who were given prior anti-cancer therapies.
Administration of Resihance 40 mg (Regorafenib) :
Resihance 40mg (Regorafenib) is recommended orally at the dosage of 160 mg (4×40mg tablets) which is taken for 21 days in a 28-day dosage cycle. In this 28-day cycle, the final 7 days are laid off to seek any sort of improvements or changes after administration. 80 mg (2×40mg tablets) is the lowest recommended dose whereas 160 mg is the highest recommended dose for a single day. Once swallowed, about 83% of the drug is readily available for absorption (bio-available) within 3 to 4 hours. Regorafenib has a high binding affinity (99.5%) with cancer cells which assists in distributing its contents throughout the region of cancer. Furthermore, regorafenib is metabolized in the liver and finally expelled (90%) from the body in 12 days after administration. If patients’ vomit after taking regorafenib, they shouldn’t take any supplementary tablets and inform their respective doctor immediately.